KR950005327A - 임파구 항원 CD2 및 종양 항원을 인식하는 이특이적 트리거(Trigger) 분자 - Google Patents

임파구 항원 CD2 및 종양 항원을 인식하는 이특이적 트리거(Trigger) 분자 Download PDF

Info

Publication number
KR950005327A
KR950005327A KR1019940018956A KR19940018956A KR950005327A KR 950005327 A KR950005327 A KR 950005327A KR 1019940018956 A KR1019940018956 A KR 1019940018956A KR 19940018956 A KR19940018956 A KR 19940018956A KR 950005327 A KR950005327 A KR 950005327A
Authority
KR
South Korea
Prior art keywords
aicd2
bab
mab
bispecific antibody
antibody
Prior art date
Application number
KR1019940018956A
Other languages
English (en)
Other versions
KR100347465B1 (ko
Inventor
스트리트마테르 볼프강
죄글레 카르로타-실비아
모우어 스테판
슈라벤 부르크하르트
빌트 마르틴
Original Assignee
위르겐 호이만, 라인하르트 슈틀러
메르크 파텐트 게젤샤프트 미트 베쉬랭크터 하프퉁
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 위르겐 호이만, 라인하르트 슈틀러, 메르크 파텐트 게젤샤프트 미트 베쉬랭크터 하프퉁 filed Critical 위르겐 호이만, 라인하르트 슈틀러
Publication of KR950005327A publication Critical patent/KR950005327A/ko
Application granted granted Critical
Publication of KR100347465B1 publication Critical patent/KR100347465B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Abstract

본 발명읜 임파구 CD2 항원 및 기타 가변 종양 항원을 인식하는 매우 효과적인 신규의 이특이적 항체 단편에 관한 것이다. 더욱이 본 발명은 AICD2. M1 및 AICD2. M2로 명명된 2개의 신규 모노클론 항체에 관한 것이다. 이들중 최소한 하나가 이특이적 항체 단편인 이들항체의 결합은 종양 치료 및 진단 분야에 성공적으로 사용될 수 있다.

Description

임파구 항원 CD2 및 종양 항원을 인식하는 이특이적 트리거(Trigger) 분자
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. BAb<X, AICD2.M1>Y 또는 BAb<X, AICD2.M2>Y로 표시되는, 종양 세포의 에피토프에 대한 제1결합 부위 및 CD2 항원의 에피토프에 대한 제2결합 부위를 포함하는, 종양 세포의 용해에 유용한 이특이적 항체 분자 : 상기 표식에서, BAb는 이특이적 항체를 의미하고, X는 종양 항원을 인식하는 항체 결정기이고, AICD2.M1 및 AICD2.M2는 CD2 항원을 인식하는 항체이고, Y는 전체 항체의 일부이다.
  2. 제1항에 있어서, X가 모노클론 항체 MAb 425, MAb 361 또는 MAb 15로부터 유도되는 항체 결정기인 이특이적 항체 분자.
  3. 제1항 또는 제2항에 있어서, Y가 F(ab′)2 분자인 이특이적 항체 분자.
  4. 제1항 또는 제3항중 어느 한 항에 있어서, BAb<425, AICD2.M1>F(ab′)2, BAb<425, AICD2.M2>F(ab′)2, BAb<361, AICD2.M1>F(ab′)2, BAb<361, AICD2.M2>F(ab′)2, BAb<15, AICD2.M1>F(ab′)2, 및 BAb<15, AICD2.M2>F(ab′)2로 구성되는 군으로부터 선택되는 이특이적 항체 분자.
  5. 하나 또는 그 이상의 이황화 결합에 의해 연결된, 각각 2개의 동일한 L(경쇄-H(중쇄) 반(half) 분자를 포함하는 2개의 다른 모노클론 항체를 2개의 F(ab′)2 분자로 효소적 방법에 의해 전환시키고, 환원 조건하에서 각 F(ab′) 분자를 Fab′티올로 절단시키고, 이러한 각 항체의 Fab′분자중의 하나를 티올 활성화제로 유도체화하고, 종양 특이성을 가지는 활성화된 Fab′분자를 임파구 특이성을 가지는 비-활성화된 Fab′분자와 결합시키거나 또는 그 역으로 결합시켜 원하는 이특이적 항체 F(ab′)2 단편을 얻음으로써, 종양 세포의 에피토프에 대한 제1결합 부위 및 CD2항원의 에피토프에 대한 제2결합 부위를 포함하며, 모노클론 항체 AICD2.M1 및 AICD2.M2를 임파구 항원을 인식하는 항체로서 사용함을 특징으로 하는, 종양 세포의 용해에 유용한 이특이적 항체 F(ab′)단편의 제조방법.
  6. 제5항에 있어서, MAb 425, MAb 361 또는 MAb 15를 종양 세포를 인식하는 항체로 사용함을 특징으로 하는 방법.
  7. 세포주 1H 10(국제 기탁번호 DSM ACC2118)로부터 단리하여 얻어질 수 있는, 항원 CD2를 인식하는 모노클론 항체 AICD2.M1.
  8. 세포주 7D 3(국제 기탁번호 DSM ACC2119)로부터 단리하여 얻어질 수 있는, 항원 CD2를 인식하는 모노클론 항체 AICD2.M2.
  9. 하나 또는 그 이상의 약학적으로 허용가능한 담체, 부형제 또는 희석제와 함께, 제1항 내지 제4항 중 어느 한 항에 따른 하나 이상의 이특이적 항체 단편을 활성 성분으로서 포함하는 약학 제제.
  10. 이특이적 항체 단편 BAb<X, AICD2.M2>Y를 포함하는 제9항에 따른 제1약학 제제(I) 및 MAb AICD2.M1 또는 MAb<AICD2.M2>Y 또는 BAb<X, AICD2.M1>Y(여기서, X 및 Y는 제1항에서 정의한 바와 같다)를 포함하는 별도의 제2약학제제를 포함하는 약학적 킷트.
  11. 이특이적 항체 단편 BAb<X, AICD2.M1>Y를 포함하는 제9항에 따른 제1약학 제제 및 MAb AICD2.M2 또는 MAb<AICD2.M2>Y 또는 BAb<X, AICD2.M2>Y(여기서, X 및 Y는 제1항에서 정의한 바와 같다)를 포함하는 별도의 제2약학제제를 포함하는 약학적 킷트.
  12. 제11항에 있어서, 제제(I)이 이특이적 항체 단편 BAb<425, AICD2.M1>F(ab′)2 또는 BAb<361, AICD2.M1>F(ab′)2 또는 BAb<15, AICD2.M1>F(ab′)2를 포함하고, 제제(II)가 MAb<AICD2.M2>F(ab′)2를 포함하는 약학적 킷트.
  13. 부가적인 T-임파구의 임의적 존재하에 제10항 내지 제12항중 어느 한 항에 따른 약학적 킷트를 이용하여 종양 세포를 제제 (I)으로 처리한 후 제제(II)로 처리한 다음, 임의적으로 기존의 정제단계를 수행하는, 자가유래 골수 이식에서 생체의 종양 세포의 정화방법.
  14. 사람의 종양 치료 약물을 제조하기 위한, 제1항 내지 제4항중 어느 한 항에 따른 이특이적 항체 단편의 용도.
    ※참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019940018956A 1993-08-02 1994-08-01 임파구항원cd2및종양항원을인식하는이특이적트리거분자 KR100347465B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93112330 1993-08-02
EP93112330.1 1993-08-02

Publications (2)

Publication Number Publication Date
KR950005327A true KR950005327A (ko) 1995-03-20
KR100347465B1 KR100347465B1 (ko) 2003-03-03

Family

ID=8213129

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940018956A KR100347465B1 (ko) 1993-08-02 1994-08-01 임파구항원cd2및종양항원을인식하는이특이적트리거분자

Country Status (20)

Country Link
US (1) US5798229A (ko)
EP (1) EP0637593B1 (ko)
JP (2) JP3822653B2 (ko)
KR (1) KR100347465B1 (ko)
AT (1) ATE199378T1 (ko)
AU (1) AU683659B2 (ko)
CA (1) CA2129183C (ko)
CZ (1) CZ291071B6 (ko)
DE (1) DE69426743T2 (ko)
DK (1) DK0637593T3 (ko)
ES (1) ES2156587T3 (ko)
GR (1) GR3035926T3 (ko)
HU (1) HU218100B (ko)
NO (1) NO942850L (ko)
PL (1) PL176761B1 (ko)
PT (1) PT637593E (ko)
RU (1) RU2203319C2 (ko)
SK (1) SK283133B6 (ko)
UA (1) UA40577C2 (ko)
ZA (1) ZA945753B (ko)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0826695B1 (de) * 1996-09-03 2001-12-12 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Zerstörung von kontaminierenden Tumorzellen in Stammzelltransplantaten mit bispezifischen Antikörpern
EP0826696B1 (de) * 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
US6863887B1 (en) * 1998-03-30 2005-03-08 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
CA2731416A1 (en) 1998-03-30 1999-10-07 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
ES2267275T3 (es) * 1998-07-10 2007-03-01 Connex Gmbh Reactivo inmunologico que interacciona especificamente con el dominio extracelular de la cadena zeta humana.
WO2000018806A1 (de) * 1998-09-25 2000-04-06 Horst Lindhofer Bispezifische und trispezifische antikörper, die spezifisch mit induzierbaren oberflächenantigenen als operationelle zielstrukturen reagieren
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
CA2442066C (en) 2001-04-02 2005-11-01 Wyeth Pd-1, a receptor for b7-4, and uses therefor
AT502293B1 (de) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
JP4596916B2 (ja) * 2002-09-05 2010-12-15 メディミューン，エルエルシー Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法
RS20050300A (en) 2002-10-16 2007-08-03 Euro-Celtique S.A., Antibodies that bind cell-associated ca 125/0772p and methods of use thereof
WO2004087759A2 (en) * 2003-03-28 2004-10-14 Elusys Therapeutics, Inc. Method and compositions for conversion of antibody activity
AU2004256021A1 (en) * 2003-05-09 2005-01-20 University Of Massachusetts Non-human animals expressing heterologous complement receptor type 1 (CR1) molecules on erythrocytes and uses therefor
JP2007510738A (ja) * 2003-11-06 2007-04-26 アイコス、コーポレーション ＣＤ１１ｄ（α−ｄ）インテグリンに特異的に結合する組成物を使用した慢性疼痛を処置する方法
WO2005057223A2 (en) * 2003-12-04 2005-06-23 Applied Research Systems Ars Holding N.V. Methods for identifying modulators of active kit tyrosine kinase receptor
JP2008518947A (ja) * 2004-10-29 2008-06-05 エルシス セラピューティクス， インク． 免疫応答のクリアランス及び誘導におけるｃｒ１結合分子の使用
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
ES2568436T3 (es) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
SG10201605394SA (en) 2007-09-26 2016-08-30 Chugai Pharmaceutical Co Ltd Modified Antibody Constant Region
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) * 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) * 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
JP2011518313A (ja) 2008-01-15 2011-06-23 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 急性骨髄性白血病幹細胞のマーカー
AU2009296392B2 (en) 2008-09-26 2016-06-02 Dana-Farber Cancer Institute, Inc. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
PT3903829T (pt) 2009-02-13 2023-06-02 Immunomedics Inc Imunoconjugados com uma ligação intracelular clivável
US20160095939A1 (en) 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP5501439B2 (ja) 2009-04-02 2014-05-21 ロシュ グリクアート アクチェンゲゼルシャフト 完全長抗体と単鎖Ｆａｂフラグメントとを含む多重特異的抗体
KR101456326B1 (ko) 2009-04-07 2014-11-12 로슈 글리카트 아게 3가, 이중특이적 항체
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
PL2477648T3 (pl) 2009-09-15 2022-11-07 The Board Of Trustees Of The Leland Stanford Junior University Synergistyczna terapia anty-cd47 dla nowotworów hematologicznych
CN104945509A (zh) 2009-09-16 2015-09-30 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
EP2481752B1 (en) 2009-09-24 2016-11-09 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
US8968740B2 (en) 2009-11-13 2015-03-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
CA2782194C (en) 2009-12-02 2018-01-16 Immunomedics, Inc. Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
EP3511023A1 (en) * 2009-12-02 2019-07-17 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
RU2606264C2 (ru) * 2009-12-25 2017-01-10 Чугаи Сеияку Кабушики Каиша Способ полипептидной модификации для очистки полипептидных мультимеров
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
RU2624027C2 (ru) * 2010-04-23 2017-06-30 Дженентек, Инк. Получение гетеромультимерных белков
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
MY166429A (en) 2010-11-17 2018-06-26 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
BR112013013311A2 (pt) 2010-11-30 2017-09-19 Chugai Pharmaceutical Co Ltd agente terapêutico de indução de citotoxicidade
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2681240B1 (en) 2011-02-28 2017-08-16 F. Hoffmann-La Roche AG Monovalent antigen binding proteins
EP2681239B8 (en) 2011-02-28 2015-09-09 F. Hoffmann-La Roche AG Antigen binding proteins
TWI743461B (zh) * 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012151199A1 (en) 2011-05-02 2012-11-08 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
MX359384B (es) 2011-10-11 2018-09-25 Genentech Inc Conjunto mejorado de anticuerpos bisespecificos.
CN104159921B (zh) * 2011-12-15 2018-05-04 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
BR112014019579A2 (pt) 2012-02-10 2019-10-15 Genentech, Inc Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
EP2879710B1 (en) 2012-08-03 2019-11-13 Dana-Farber Cancer Institute, Inc. Medical uses of agents that modulate immune cell activation and corresponding screening methods
EP3586874A1 (en) 2012-08-14 2020-01-01 IBC Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
EP4035689A1 (en) 2012-12-13 2022-08-03 Immunomedics Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
EP3293275B1 (en) 2013-06-06 2021-08-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
US20160175401A1 (en) 2013-07-31 2016-06-23 Dana-Farber Cancer Institute Inc. Compoitions and methods for modulating thermogenesis using pth-related and egf-related compounds
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
KR102441231B1 (ko) 2013-09-27 2022-09-06 추가이 세이야쿠 가부시키가이샤 폴리펩티드 이종 다량체의 제조방법
WO2015052230A1 (en) 2013-10-11 2015-04-16 F. Hoffmann-La Roche Ag Multispecific domain exchanged common variable light chain antibodies
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US11046763B2 (en) 2014-01-08 2021-06-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
AU2015219495B2 (en) 2014-02-21 2019-11-21 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
CN106029098A (zh) 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
DK3126383T3 (en) 2014-04-03 2019-04-01 Igm Biosciences Inc MODIFIED J-CHAIN
EP2930188A1 (en) * 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
EP3148580B1 (en) 2014-05-29 2021-01-20 MacroGenics, Inc. Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
EP3160504B1 (en) 2014-06-24 2020-09-16 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
ES2764111T3 (es) 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
AU2015360903B2 (en) 2014-12-08 2021-03-25 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
DK3265575T3 (da) 2015-03-04 2021-05-31 Igm Biosciences Inc Cd20-bindende molekyler og anvendelser deraf
CN108368169A (zh) 2015-03-18 2018-08-03 约翰霍普金斯大学 靶向钾通道kcnk9的新的单克隆抗体抑制剂
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER
CN107428837A (zh) 2015-04-22 2017-12-01 免疫医疗公司 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
PT3313443T (pt) 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
SI3316885T1 (sl) 2015-07-01 2021-09-30 Immunomedics, Inc. Imunokonjugati protitelo-SN-38 z linkerjem CL2A
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
DK3356401T3 (da) 2015-09-30 2020-09-07 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
AU2016329197B2 (en) 2015-09-30 2021-01-21 Igm Biosciences, Inc. Binding molecules with modified J-chain
US11207393B2 (en) 2015-10-16 2021-12-28 President And Fellows Of Harvard College Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
EP3433365B1 (en) 2016-03-21 2023-08-02 Dana-Farber Cancer Institute, Inc. T-cell exhaustion state-specific gene expression regulators and uses thereof
WO2018036852A1 (en) 2016-08-25 2018-03-01 F. Hoffmann-La Roche Ag Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
WO2018112033A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs
EP3558360A1 (en) 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
RU2663104C1 (ru) * 2017-07-13 2018-08-01 Общество с ограниченной ответственностью "Реал Таргет" Получение пегилированных фрагментов gd2-специфичных антител, индуцирующих прямую клеточную гибель gd2-позитивных опухолевых клеток, и их применение в терапии gd2-позитивных опухолей
EP3972993A1 (en) * 2019-05-21 2022-03-30 Novartis AG Variant cd58 domains and uses thereof
EP4342497A1 (en) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antibody having reduced binding affinity for antigen
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
WO2023201226A1 (en) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
WO2024059183A1 (en) 2022-09-14 2024-03-21 President And Fellows Of Harvard College Methods and compositions for modulation of piezo1 in the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260880A3 (en) * 1986-09-11 1990-03-07 Dana-Farber Cancer Institute, Inc. Turning on of cytotoxicity
EP0294703B1 (en) * 1987-06-10 1995-05-10 Dana-Farber Cancer Institute, Inc. Bifunctional antibody constructs and method for selectively destroying cell populations
AU6290090A (en) * 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
CZ282603B6 (cs) * 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanizované a chimerické monoklonální protilátky

Also Published As

Publication number Publication date
NO942850L (no) 1995-02-03
JP3822653B2 (ja) 2006-09-20
PT637593E (pt) 2001-08-30
GR3035926T3 (en) 2001-08-31
SK283133B6 (sk) 2003-03-04
CA2129183C (en) 2006-05-16
US5798229A (en) 1998-08-25
CZ291071B6 (cs) 2002-12-11
DE69426743D1 (de) 2001-04-05
UA40577C2 (uk) 2001-08-15
HUT71309A (en) 1995-11-28
PL304510A1 (en) 1995-02-06
ATE199378T1 (de) 2001-03-15
DK0637593T3 (da) 2001-06-25
HU218100B (hu) 2000-06-28
JP2005336207A (ja) 2005-12-08
JP4231862B2 (ja) 2009-03-04
CA2129183A1 (en) 1995-02-03
PL176761B1 (pl) 1999-07-30
CZ180294A3 (en) 1995-02-15
AU683659B2 (en) 1997-11-20
EP0637593A1 (en) 1995-02-08
SK91294A3 (en) 1996-11-06
DE69426743T2 (de) 2001-08-16
JPH0789873A (ja) 1995-04-04
KR100347465B1 (ko) 2003-03-03
ES2156587T3 (es) 2001-07-01
HU9402220D0 (en) 1994-10-28
RU2203319C2 (ru) 2003-04-27
RU94028282A (ru) 1996-07-20
ZA945753B (en) 1995-03-15
NO942850D0 (ko) 1994-08-01
AU6869894A (en) 1995-02-09
EP0637593B1 (en) 2001-02-28

Similar Documents

Publication Publication Date Title
KR950005327A (ko) 임파구 항원 CD2 및 종양 항원을 인식하는 이특이적 트리거(Trigger) 분자
RU2421464C2 (ru) Человеческие антитела к il-13 и их терапевтическое применение
DE60331910D1 (de) Antikörper gegen humanes cd22 und deren therapeutische und diagnostische verwendungen
JP2002518460A5 (ko)
ATE477276T1 (de) Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
HUP0300806A2 (hu) A humán IL-1béta-nak megfelelő antitestek
NI200600098A (es) Anticuerpos que se unen al receptor de interleuquina-4
BRPI9809391B8 (pt) processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
DE60224291D1 (de) System zur antikörperexpression und- synthese
KR920701465A (ko) Cd4 특이적 재조합 항체
EE05496B1 (et) Antikeha, mis seob osteoprotegeriini siduvat valku
ATE460946T1 (de) Gebrauch von bispezifischen antikörpern in diagnose und therapie
ES2231826T3 (es) Anticuerpos monoclonales anti-cd6 para el tratamiento y el diagnostico de la psoriasis.
TW200500377A (en) Method of humanizing immune system molecules
EP1705191A3 (en) Anti-interleukin-18 antibody
NO913428L (no) Humant intra-acrosomalt sperma-antigen for anvendelse i en befruktningshindrende vaksine.
DE69939312D1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
BR0207151A (pt) Moléculas de aglutinação terapêuticas
EA200401081A1 (ru) Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro
KR900013986A (ko) 종양-관련항원에 대한 모노클로날 항체(MAb_s), 이의 제조방법 및 용도
Sandberg et al. Initiation of bone resorption by the classical and alternative C pathways and its mediation by prostaglandins
EP0350690A3 (de) Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente
ATE353337T1 (de) Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet
CA2449488A1 (en) Compositions and methods for treating hyperimmune response in the eye
IT1284076B1 (it) Frammenti f(ab&#39;)2 e relative immunoglobuline igg, attivi come anticorpi specifici verso farmaci e i loro metaboliti, e loro

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20080701

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee